Current Trends in Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases

There are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending on their PD-L1 status. Chemotherapy works as salvage therapy for late-line recurrent/relapsed patients.

• Targeted therapy in NSCLC is a highly competitive and differentiated space covering ten different actionable biomarkers.
• Treatment development for EGFR mutations shifts from label expansion and CNS activity to overcoming resistance mechanisms.
• The relatively quiet ALK and ROS1 segments are to be reshaped by Nuvalent's TKIs with better efficacy and safety.
• Small molecule + anti-PD-1 combo therapy will unlock new first-line opportunity in the KRAS G12C segment.

Scope

• This report includes ten actionable biomarkers in NSCLC that are addressed by targeted therapy agents across multiple lines of therapy. Current and future state of these market segments is included in the scope of the report.